The ENABLE project
Funding and supporting European antibacterial drug discovery against gram negative pathogens

www.nd4bb-enable.eu
ENABLE – Introduction

Public private partnership in Europe
Innovative Medicines Initiative: Joint private (EFPIA) and public (European Commission) effort to address key bottlenecks in healthcare improvement

European consortium to develop novel anti-infectives
Core consortium of expert partners for the development of anti-infectives to clinic - including universities, small companies and EFPIA companies

€85 million over 6 years to fund novel programmes to clinic
• Funding for novel gram negative programmes to join the project
• Programme owners work in collaboration to accelerate programmes to clinic
• 3.5 years left on the clock
ENABLE – Goals and Objectives

The challenge:
One of the major challenges in antibiotic discovery is turning Hits and Leads into development candidates – finance, skills, route to clinic and market

ENABLE Objectives:
Increase the overall pipeline in the antibacterial area through external programmes feeding into a development ‘engine’

ENABLE Goals:
Target the systemic treatment of infections due to resistant Gram-negative bacterial pathogens *E. coli*, *K. pneumoniae*, *P. aeruginosa* and *A. baumannii*
• identify three antibacterial Leads
• identify two antibacterial development Candidates
• progress at least one compound into Phase 1 clinical studies
ENABLE – what does it look like?

• Gram negative programmes with data to indicate potential submit 3 page expression of interest to the project – single applicant
• Thresholds to meet – MIC, cytotox etc, demonstrate potential and innovation
• Reviewed by external experts to assess fit to thresholds
• Develop detailed data pack for presentation to the Portfolio Management Committee (PMC)
• If approved – collaborative workplan developed and costed
• Programme owner joins consortium as a formal partner
• Targets set by the PMC to meet
• Reviewed each three months by PMC to assess progress
• If targets met, green light
• If targets missed, programme adaptation or termination
ENABLE – let’s talk money

• Eligible for funding: Small companies, universities and research organisations within the EU and associated countries such as Israel, Norway and Switzerland
• Individual programmes have a budget split between the 3-4 partners working upon them; each partner will receive funding for their work
• Eligible costs include direct costs (staff, consumables) plus a 20% indirect cost - funded at 75%
• All work approved for each programme is eligible, including clinical trials
• Subcontracting possible for skills not found within consortium – contract with programme owner
ENABLE – IP and exploitation

• Critical that programmes are able to reach market – not just science but also investment and future partnerships
• All IP associated with programme is retained by programme owner – including new IP generated within the project
• Partners have access to foreground IP for delivery of project activities but no permission for non-programme use
• Limited revenue sharing when cash generated by programme (as all partners contribute financially) – small % of income with cap on maximum dependant on how much ENABLE has contributed to development
IMI eligible partners

- To be eligible for IMI funding, organisations must be EU registered, small companies, research organisations or non-profit organisations.
- HOWEVER – non-SMEs and other European organisations can participate in ENABLE with programmes, they do not receive funds for their own role in the development programme.
- Priority to EU-based programmes, funded by the EU taxpayer...
- Programmes will also be approved based on ENABLE portfolio – minimise duplication.
- If non-EU?
  - Licence programmes into EU partners, examples in project already.
  - Come to Europe! The food and company are great!
Next step

• Talk to me and ENABLE colleagues (Frederik Deroose) – Not a one size fits all programme
• Advice in confidence
• [http://www.nd4bb-enable.eu/open-calls](http://www.nd4bb-enable.eu/open-calls)
• Support through generation of EoI